A new trading day began on Tuesday, with Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) stock price up 0.60% from the previous day of trading, before settling in for the closing price of $33.11. CRNX’s price has ranged from $24.10 to $62.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 50.01% over the last five years. Meanwhile, its annual earnings per share averaged -10.98%. With a float of $87.08 million, this company’s outstanding shares have now reached $92.93 million.
The firm has a total of 437 workers. Let’s measure their productivity. In terms of profitability, gross margin is -18.09%, operating margin of -32675.07%, and the pretax margin is -28720.69%.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 6.99%, while institutional ownership is 103.93%. The most recent insider transaction that took place on Mar 19 ’25, was worth 86,021. In this transaction Chief Med and Dev Officer of this company sold 2,515 shares at a rate of $34.20, taking the stock ownership to the 72,233 shares. Before that another transaction happened on Mar 19 ’25, when Company’s Chief Operating Officer sold 7,162 for $34.20, making the entire transaction worth $244,964. This insider now owns 87,491 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.49% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Here are Crinetics Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 23.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.70, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -4.38 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Analysing the last 5-days average volume posted by the [Crinetics Pharmaceuticals Inc, CRNX], we can find that recorded value of 0.94 million was lower than the volume posted last year of 1.04 million. As of the previous 9 days, the stock’s Stochastic %D was 87.36%. Additionally, its Average True Range was 1.76.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 25.41%, which indicates a significant decrease from 97.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.51% in the past 14 days, which was lower than the 60.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.75, while its 200-day Moving Average is $46.72. Now, the first resistance to watch is $33.87. This is followed by the second major resistance level at $34.42. The third major resistance level sits at $35.25. If the price goes on to break the first support level at $32.48, it is likely to go to the next support level at $31.65. Now, if the price goes above the second support level, the third support stands at $31.10.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
With a market capitalization of 3.12 billion, the company has a total of 93,629K Shares Outstanding. Currently, annual sales are 1,040 K while annual income is -298,410 K. The company’s previous quarter sales were 0 K while its latest quarter income was -76,830 K.
